NORTHEAST ALABAMA REGIONAL MED CTR
1. Target Overview & Investment Thesis
NORTHEAST ALABAMA REGIONAL MED CTR is a 295-bed safety-net/medicaid heavy in CALHOUN, AL with $209.4M in net patient revenue and a -11.8% operating margin. The hospital serves a payer mix of 27.5% Medicare, 25.2% Medicaid, and 47.3% commercial.
Thesis: Undervalued. Our ML models identify $15.4M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -11.8% to -4.4% (+736bps).
| Net Revenue HCRIS | $209.4M |
| Current EBITDA COMPUTED | $-24.7M |
| Operating Margin COMPUTED | -11.8% |
| Occupancy HCRIS | 55.8% |
| Revenue / Bed COMPUTED | $710K |
| Net-to-Gross HCRIS | 12.2% |
| Distress Probability ML | 51.4% |
2. Market Context & Competitive Position
AL has 115 Medicare-certified hospitals with a median operating margin of -8.5%. The target's margin of -11.8% places it below the state median. Among 28 size-comparable peers (148-590 beds), the median margin is -4.1%. The target's below-peer margin suggests operational improvement opportunity.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (148-590), prioritizing same-state peers. 28 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| NORTHEAST ALABAMA REGIONAL MED (Target) | AL | 295 | $209.4M | -11.8% |
| THE CHILDRENS HOSPITAL OF ALAB | AL | 351 | $839.5M | 5.8% |
| GRANDVIEW MEDICAL CENTER | AL | 404 | $615.4M | 14.2% |
| DCH REGIONAL MEDICAL CENTER | AL | 372 | $601.9M | -11.2% |
| BAPTIST MEDICAL CENTER SOUTH | AL | 348 | $595.4M | -4.8% |
| ST VINCENTS BIRMINGHAM | AL | 399 | $480.0M | -5.5% |
| SOUTHEAST HEALTH MEDICAL CENTE | AL | 353 | $427.1M | -4.4% |
| EAST ALABAMA MEDICAL CENTER | AL | 297 | $399.6M | -6.5% |
| USA HEALTH UNIVERSITY HOSPITAL | AL | 242 | $348.5M | -6.4% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $15.4M (736bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $4.4M | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $4.2M | +200bp | 12mo |
| Denial Rate Reduction | 12.0% | 6.5% | $4.1M | +198bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $2.5M | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $134K | +6bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $-24.7M |
| + RCM Uplift | +$15.4M |
| Pro Forma EBITDA | $-9.2M |
| Current Margin | -11.8% |
| Pro Forma Margin | -4.4% |
| WC Released (1x) | $8.0M |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $-37.9M | $-8.5M | 0.00x | -100.0% |
| Base (11x exit) | 10.0x | 11.0x | $-37.9M | $-21.7M | 0.00x | -100.0% |
| Bull Case | 9.0x | 11.0x | $-34.1M | $16.9M | 0.00x | -100.0% |
| Bull (12x exit) | 9.0x | 12.0x | $-34.1M | $8.3M | 0.00x | -100.0% |
| Bear Case | 11.0x | 10.0x | $-41.7M | $-73.2M | 0.00x | -100.0% |
| Bear (11x exit) | 11.0x | 11.0x | $-41.7M | $-94.1M | 0.00x | -100.0% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| High | Negative operating margin | RCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion |
| Medium | Elevated Medicaid exposure (25.2%) | Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims |
| High | Elevated distress probability | Model estimates 51.4% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk |
| Low | Low net-to-gross ratio | Large contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 28 hospitals with 148-590 beds
- Same-state prioritization (n=29)
- Comp margins: P25=-7.4% / P50=-4.1% / P75=2.3%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.